2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 271-273
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, B Cell Lymphoma, Research, Fundamental Science, Translational Research
PAPER

372 BTK inhibition remodels the CLL epigenome and exposes an NRF1-noncanonical PRC1 mitochondrial translation dependency

Zhiquan Wang, Ph.D, Daniel Bihnam, MS2, Sutapa Sinha, PhD3, Esteban Braggio, PhD4, Saad Kenderian, M.B., Ch.B.5, Sameer A. Parikh, MBBS6, Neil E Kay, M.D.7
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States

Background: Bruton tyrosine kinase inhibitors (BTKi) are highly effective in chronic lymphocytic leukemia (CLL), but resistance and relapse remain major clinical problems. The downstream epigenetic programs that mediate BTKi response and sustain CLL survival are incompletely defined. We sought to construct a chromatin-informed BTK-dependent gene-regulatory network (GRN) and identify actionable survival pathways. To do this, we studied longitudinal blood samples from patients treated with BTKi.

Methods: We profiled longitudinal CLL B cells from 53 BTKi-treated patients (ibrutinib, n=41; acalabrutinib, n=12) at pre-treatment (T1), during treatment (T2), and at relapse (T3). Paired ATAC-seq was integrated with RNA-seq and paired CUT&Tag profiling of histone marks: H3K4me1 (enhancer-associated), H3K4me3 (promoter-associated), H3K27ac (active regulatory regions), H3K27me3 (Polycomb repression), and H3K9me3 (heterochromatin). Differential regions were defined by (false discovery rate) FDR <0.05 and absolute log2 fold change >1. Each treatment-altered accessible region was linked to the nearest gene within 1 Mb and integrated with chromatin states, transcription factor (TF) motifs, and expression to construct a GRN. Candidate mechanisms were tested by CUT&RUN, CRISPR-mediated depletion of NRF1 or PCGF3 in BCR signaling-dependent or independent cells, and mitochondrial translation (MT) inhibition with the drug tigecycline.

Results: Paired ATAC-seq identified 1,713 genomic regulatory regions with altered accessibility at T2 versus T1: 1,143 became more accessible (opening) and 570 became less accessible (closing). Over the same interval, CUT&Tag identified both increases and decreases in histone-mark signals: H3K4me1 increased at 642 regions and decreased at 1,050; H3K4me3 increased at 206 and decreased at 47; H3K27ac increased at 194 and decreased at 241; H3K27me3 increased at 93 and decreased at 78; and H3K9me3 increased at 30 and decreased at 26. H3K4me1, H3K4me3, and H3K27ac changed in parallel with accessibility at opening and closing regions but remained stable where accessibility was unchanged. H3K27me3 showed no consistent relationship with accessibility, and H3K9me3 was comparatively stable. Chromatin-state analysis showed that closing regions were mainly active promoters and enhancers at T1, whereas opening regions were largely heterochromatin or lacked a defined baseline state. Paired T3 versus T1 ATAC-seq and CUT&Tag identified no significant accessibility differences, consistent with a return toward the pretreatment chromatin landscape. Linking altered regions to nearby genes showed that increased accessibility generally accompanied their increased expression, while decreased accessibility accompanied decreased expression. Integration with TF motif analysis defined a BTKi-responsive GRN and implicated PAX5, IRF8, SPIB, POU2F2, and NFAT as prominent candidate regulators.

Within the BTKi-responsive GRN, MT emerged as the leading pathway among genes linked to treatment-suppressed chromatin accessibility, indicating a coordinated leukemic survival program. Consistent with this, 42 of 60 MT genes downregulated during treatment were linked to regions that became less accessible, while MT-gene expression, promoter accessibility, and H3K27ac decreased together during treatment and returned toward pre-treatment at relapse. We next investigated the mechanism maintaining this active chromatin program. NRF1 was the leading TF motif at MT promoters and CUT&RUN showed that NRF1 co-occupied 54 of 61 MT promoters with AUTS2 and PCGF3/5, core factors of ncPRC1.3/5. Depletion of either NRF1 or PCGF3 in CLL-like MEC1 cells reduced H3K27ac at MT promoters and suppressed MT-gene expression, supporting an NRF1–ncPRC1.3/5 axis that maintains an active epigenetic state at MT genes. Functionally, tigecycline preferentially reduced the viability of primary CLL cells (n=6) compared with normal B cells (n=3) and retained activity in both BTK-WT and BTK-C481S cells, identifying MT as a targetable survival dependency that may persist in BTKi-resistant disease.

Conclusions: BTKi treatment induces coordinated remodeling of chromatin accessibility and active histone modifications in CLL, defining a BCR-associated regulatory network that re-emerges at relapse. This network identifies an NRF1-ncPRC1.3/5-controlled MT program as a targetable BTK-downstream survival dependency retained in BTKi-resistant disease.
Zhiquan Wang, Ph.D: No relevant conflicts of interest to declare.